Toward an HIV vaccine: A scientific journey-Reference-Cited by-同舟云学术

Toward an HIV vaccine: A scientific journey

Published:2015-07-24 Issue:6246 Volume:349 Page:386-387
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Fauci Anthony S.¹,Marston Hilary D.²

Affiliation:

1. Anthony S. Fauci M.D. is the Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, Bethesda, MD 20892, USA.

2. Hilary D. Marston M.D., M.P.H. is a Medical Officer and Policy Advisor for Global Health at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, Bethesda, MD 20892, USA.

Abstract

Different strategies are coming together to provide insights for an effective HIV vaccine

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference24 articles.

1. Dowdle W., Public Health Rep. 101, 232 (1986).

2. Evolutionary and immunological implications of contemporary HIV-1 variation

3. Dolin R., et al.., NIAID AIDS Vaccine Clinical Trials Network, Ann. Intern. Med. 114, 119 (1991).

4. Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV.

5. Kolata G. in New York Times 16 February 1988.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities;Vaccines;2022-03-02

2. Nanocarrier vaccines for SARS-CoV-2;Advanced Drug Delivery Reviews;2021-04

3. HIV Vaccine Development: 35 Years of Experimenting in the Funding of Biomedical Research;Viruses;2020-12-19

4. Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia;Vaccines;2020-12-01

5. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients;Cell;2020-08